Evidence map›Paper›PMID 35247923›Full record

Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2022

A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.

Chiara Colombo, Marco Fiore, Giovanni Grignani, Francesco Tolomeo, Alessandra Merlini, Elena Palassini, Paola Collini, Silvia Stacchiotti, Paolo Giovanni Casali, Federica Perrone and 2 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02547831 (Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02547831 completednot on this map

Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients

TypeobservationalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2013 to 2016Enrolled100ConditionsDesmoid-type FibromatosisArmsObservational approach
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Percutaneous Management of Desmoid Tumors.Current oncology reports · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Observational
  15. Article
  16. Article
  17. Article
  18. Review
  19. Aggressive fibromatosis of the sigmoid colon: A case report.World journal of gastrointestinal oncology · 2024
    Article
  20. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Chiara ColomboDepartment of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0001-8031-5528
Marco FioreDepartment of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0001-8220-424X
Giovanni GrignaniDivision of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Francesco TolomeoDivision of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Alessandra MerliniDivision of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Elena PalassiniCancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Paola ColliniDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0002-6158-210X
Silvia StacchiottiCancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0002-1742-8666
Paolo Giovanni CasaliCancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Federica PerroneDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Luigi MarianiUnit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0001-6208-4084
Alessandro GronchiDepartment of Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0002-4703-3534
Fondazione IRCCS Istituto Nazionale dei Tumori · ITCandiolo Cancer Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo prospectively assess the behavior of primary sporadic (not familial adenomatous polyposis-associated) desmoid fibromatosis (DF) managed by active surveillance (AS). EXPERIMENTAL:

designThis is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site. Patients were assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Primary endpoint was progression-free survival (PFS) at 3 years. Treatment-free survival (TFS) was also analyzed. PFS and TFS were calculated by Kaplan-Meier plots and compared by log-rank test. Cox proportional hazard multivariable regression analyses were performed.

resultsFrom 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm. CTNNB1 mutations were T41A (50%), S45F (12%), other (19%), wild-type (19%). At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%). Larger tumor size and extremity location were associated to shorter TFS and a trend for S45F mutation was also observed (P = 0.06), while none of the mentioned variables was significantly associated with PFS.

conclusionsIn primary DF, AS can be proposed, because disease stabilization and spontaneous regression frequently occur. However, extra care should be taken for patients with tumors of larger size, extremity location, and S45F mutation. See related commentary by Greene and Van Tine, p. 3911.

Indexed as

Desmoid TumorsAdultbeta CateninFemaleHumansMalePrognosisProspective StudiesWatchful Waitingbeta Catenin

Identifiers

PMID35247923
OpenAlexW4220817358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.